Mr. Chris Taves reports

MEDIPHARM LABS ANNOUNCES BOARD OF DIRECTORS CHANGES: SHELLEY POTTS STEPS DOWN, MICHAEL BUMBY RETURNS

Shelley Potts will step down from Medipharm Labs Corp.'s board of directors, effective Dec. 31, 2025. The company also announced that Michael Bumby will be rejoining the board, effective Jan. 1, 2026, bringing extensive experience in finance and governance to support Medipharm's strategic priorities.

Mr. Bumby previously served on the board and was chief financial officer at Vivo Cannabis Inc., which Medipharm acquired in 2023. In addition to his experience in the cannabis sector, he has held senior leadership roles in global pharmaceutical companies, providing strategic and financial oversight across highly regulated markets. His combined expertise in pharma and cannabis will support Medipharm Labs' continued advancement in pharmaceutical cannabinoids.

Chris Taves, chair of the board, commented: "On behalf of the board and the entire Medipharm Labs team, I want to thank Shelley for her valuable contributions and leadership during her tenure. Shelley has been a board member since 2020 and has helped guide the company's stable growth through some of the cannabis industry's early turbulent times. Shelley has been a strong voice for good corporate governance and thoughtful financial discipline throughout her tenure.

"We are also pleased to welcome Michael back to the board. His financial expertise and prior experience with Vivo and Medipharm will provide additional valuable depth and perspective to the board."

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products utilizing a good manufacturing practice certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing practices licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the U.S. Food and Drug Administration.

In 2023, Medipharm acquired Vivo Cannabis, which expanded Medipharm's reach to medical patients in Canada through the Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GmbH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

The company carries out its operations in compliance with all applicable laws in the countries in which it operates.

We seek Safe Harbor.